David Rind, ICER CMO

In draft re­port, ICER says Amy­lyx's ALS drug would not be cost ef­fec­tive if priced sim­i­lar­ly to old­er treat­ment

Rough­ly 24 hours af­ter Cana­di­an reg­u­la­tors gave Amy­lyx Phar­ma­ceu­ti­cals the thumbs-up for its new ALS drug, ICER is out with a new analy­sis try­ing to de­ter­mine whether the drug would be cost ef­fec­tive. And the short an­swer is no — for now.

Though Amy­lyx has not dis­closed how much it in­tends to charge for the drug, brand­ed as Al­bri­oza, ICER pegged its es­ti­mat­ed cost to an old­er ALS med­i­cine, edar­avone. If Al­bri­oza costs $169,000 per year, as edar­avone cur­rent­ly does, the drug would not be cost ef­fec­tive to the US health­care sys­tem, and far from it, ICER says.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.